Roles of STAT3 in leukemia (Review)

作者：Yin Shi, Zhen Zhang, Xintao Qu, Xiaoxiao Zhu, Lin Zhao, Ran Wei, Qiang Guo, Linlin Sun, Xunqiang Yin, Yunhong Zhang, Xia Li · 发表于：International Journal of Oncology · 年份：2018 · DOI：10.3892/ijo.2018.4386 · 被引用次数：32 · 研究领域：Cytokine Signaling Pathways and Interactions、Cancer Mechanisms and Therapy、Cell death mechanisms and regulation

Leukemia is a type of hematopoietic malignancy, and the incidence rate in the United States and European Union increases by an average of 0.6 to 0.7% annually. The incidence rate in China is approximately 5.17/100,000 individuals, and the mortality rate is 3.94/100,000 individuals. Leukemia is the most common tumor affecting children and adults under 35 years of age, and is one of the major diseases leading to the death of adolescents. Signal transducer and activator of transcription 3 (STAT3) is a vital regulatory factor of signal transduction and transcriptional activation, and once activated, the phosphorylated form of STAT3 (p-STAT3) is transferred into the nucleus to regulate the transcription of target genes, and plays important roles in cell proliferation, differentiation, apoptosis and other physiological processes. An increasing number of studies have confirmed that the abnormal activation of STAT3 is involved in the development of tumors. In this review, the roles of STAT3 in the pathogenesis, diagnosis, treatment and prognosis of leukemia are discussed in the aspects of cell proliferation, differentiation and apoptosis, with the aim to further clarify the roles of STAT3 in leukemia, and shed light into possible novel targets and strategies for clinical diagnosis and treatment.